Biorelate Ltd.

Based in the UK, Biorelate Ltd. specializes in advanced data curation technologies for the biopharmaceutical sector, leveraging its proprietary platform, Galactic AI™, to enhance drug discovery processes. Biorelate Ltd. is a biopharmaceutical data curation company founded in 2014 by Daniel Jamieson, who serves as the CEO.

The company is headquartered in Manchester, UK. Since its inception, Biorelate has successfully completed 3 deals, with its most recent deal occurring on November 28, 2022, during which it raised GBP 8. 15 million in Series A funding. This round was co-led by YFM Equity Partners and Maven VCT, with participation from Manchester Tech Trust and Triple Point Ventures.

The total amount raised by the company to date is GBP 8. 15 million, leading to a current company valuation of GBP 23. 943 million. Biorelate specializes in advanced data curation technologies within the biopharmaceutical sector, primarily through its flagship platform, Galactic AI™.

This innovative product utilizes sophisticated algorithms and natural language processing to analyze extensive biomedical literature, including journals, patents, and clinical trials, to identify and curate relevant cause-and-effect relationships among drugs, genes, and diseases. By streamlining the data curation process, Galactic AI™ aims to accelerate drug discovery and target validation for researchers, data scientists, and biopharmaceutical professionals. Key clients include globally recognized pharmaceutical companies such as Pfizer and AstraZeneca, alongside dynamic biotech firms, which utilize Biorelate's services for innovative drug target selection and biomarker identification. Biorelate's technology is utilized across various geographical markets, including North America, Europe, and Asia, reflecting its global reach in addressing critical challenges in drug discovery and development.

Biorelate generates revenue primarily through a subscription-based model for its Galactic AI™ platform and related services. Clients typically engage in annual or multi-year contracts, granting access to the platform's data curation capabilities and analytical tools tailored to their specific research needs. The transactions often involve partnerships with large pharmaceutical companies and biotech firms, which leverage Galactic AI™ for efficient drug target identification and evidence-based decision-making in scientific research. The pricing structure is designed to accommodate different tiers of service and access points, ensuring that organizations, whether large multinationals or small biotechs, can find a suitable solution for their data curation and analysis requirements.

In November 2022, Biorelate Ltd. raised GBP 8. 15 million in Series A funding to enhance its operations. The company plans to utilize these funds to expand its commercial and technical teams, with a specific focus on growth in the US market.

Future developments include potential new products and services aimed at enhancing their data curation capabilities, although specific product launches and release dates have not been disclosed.